title: [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
abstract: OBJECTIVE
  To investigate the relationship between the expression of ERCC1, BRCA1, β-tubulin and K-ras and the clinical efficacy, prognosis in advanced non-small cell lung cancer treated by platinum-based chemotherapy.
  
  
  METHODS
  Expression of ERCC1, BRCA1, β-tubulin and K-ras proteins were detected by immunohistochemistry in 136 patients. The relation between gene protein expression and efficacy, prognosis was analyzed.
  
  
  RESULTS
  (1) The efficacy of chemotherapy (ORR) in the ERCC1 negative group was better than that in the ERCC1 positive group (38.6% vs.26.4%, P < 0.017). The median survival time in the ERCC1 negative group was longer than that in the ERCC1 positive group (15 months vs. 12 months, P < 0.05). There was no significant difference in PFS. (2) The clinical stage in the BRCA1 negative group was earlier than that of positive group. There was no significant difference in ORR in either the BRCA1 negative group or BRCA1 positive group. But both MST and PFS in the BRCA1 negative group was longer than that in the BRCA1 positive group (16 months vs. 9 months, P < 0.05 and 7 months vs. 7 months, P < 0.05), respectovely. (3) There were no significant differences between the β-tubulin negative group and positive group in MST, PFS and ORR. (4) The ORR in the K-ras negative group was better than that in the K-ras positive group. There was no significant difference between the K-ras negative and positive groups in MST and PFS. (5) ERCC1 protein was an independent prognostic factor determined by multivariate analysis.
  
  
  CONCLUSIONS
  Multi-biomarker detection may provide important predictive value for chemotherapy efficacy and prognosis in advanced NSCLC.
authors.affiliation: Department of Oncology, the First Affiliated Hospital, Xinjiang Medical University, Urumqi 830011, China. zhangli9514@126.com
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Ting
authors.initials: T
authors.lastname: Liu
authors.forename: Jian-qing
authors.initials: JQ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000378:metabolism*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000378:metabolism*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012074:Remission Induction; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use; D014404:Tubulin / Q000378:metabolism*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D018631:ras Proteins / Q000378:metabolism; D000093542:Gemcitabine
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D004268:DNA-Binding Proteins; D043823:Taxoids; D014404:Tubulin; D003841:Deoxycytidine; D014747:Vinblastine; D016190:Carboplatin; C071447:ERCC1 protein, human; D004720:Endonucleases; D018631:ras Proteins; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine